We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lipid Levels from Non-Fasting Patients Deemed Suitable for Assessing CVD Risk

By LabMedica International staff writers
Posted on 04 Jun 2019
Print article
Image: A new study suggests fasting may not be necessary to ensure accurate test results when assessing CVD risk (Photo courtesy of Harvard Medical School).
Image: A new study suggests fasting may not be necessary to ensure accurate test results when assessing CVD risk (Photo courtesy of Harvard Medical School).
Results published in a recent paper suggested strongly that lipid levels measured in blood samples from non-fasting patients were accurate and predicative of future cardiovascular risk.

A team of investigators from Brigham and Women's Hospital (Boston, MA, USA), Harvard Medical School (Boston, MA, USA), and Imperial College London (United Kingdom) sought to determine how non-fasting lipid levels compared with fasting lipid levels measured in the same individuals for assessing cardiovascular risk, and what was their association with incident cardiovascular events.

To this end they performed a secondary analysis of the results of a randomized clinical trial that included 8270 of 10,305 participants from the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) with non-fasting and fasting lipid levels measured four weeks apart (including 6855 participants with no prior vascular disease). Data were collected from February 1, 1998, to December 31, 2002, and analyzed from February 1, 2016, to November 30, 2018.

Analysis of the results revealed that among the 8270 participants (82.1% male; mean age, 63.4 years), non-fasting samples had modestly higher triglyceride levels and similar cholesterol levels compared to fasting samples. Associations of non-fasting lipid levels with coronary events were similar to those for fasting lipid levels.

"We hope this study will be the final nail in the coffin, providing strong evidence that, within the same person, fasting or not before a lipid level test does not matter for predicting cardiovascular risk," said senior author Dr. Samia Mora, director of the center for lipid metabolomics at Brigham and Women's Hospital. "This should reassure health care providers and patients that it does not make a difference if you fast or do not fast if the goal is to predict your cardiovascular risk."

"We spend most of our lives in a non-fasting state. And for some patients, especially those who are elderly or have diabetes, it can be risky to fast before lipid testing," said Dr. Mora. "Health care providers held back because of concerns of variability within individuals, but the data here is so convincing. It should allow people to feel more comfortable with non-fasting lipid testing for cardiovascular risk assessment, including when taking a statin."

The paper was published in the May 28, 2019, online edition of the journal JAMA Internal Medicine.

Related Links:
Brigham and Women's Hospital
Harvard Medical School
Imperial College London
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more